Leon Kaulen
@kaulen_leon
Followers
106
Following
417
Statuses
35
Neurologist @uniklinik_hd | Clinician Scientist @HdNeurooncology @DKFZ, @MGHNeuroOnc | Interested in CNS lymphomas and development of personalized therapies
Heidelberg, Germany
Joined April 2020
Pleased to share our 📰, which defines the genetics of EBV+ PCNSL using WES/RNASeq. Our work establishes EBV+ PCNSL as a distinct molecular entity and identifies alterations, which pave the way for targeted therapies. @HdNeurooncology @DKFZ @NeuroOnc 🧵:
2
2
15
Excited to share the MGH institutional experience of r/r neurolymphomatosis managed with CD19-CAR. Treatment was well tolerated and showed promising efficacy. Findings suggest CD19-CAR may sufficiently penetrate the blood nerve barrier. @MGHNeuroOnc @MGHNeurology @HdNeurooncology
CD19-directed chimeric antigen receptor T-cells provide a novel therapeutic avenue for recurrent neurolymphomatosis, a distinct NHL subtype with unmet medical need #CART #hemonc
1
6
17
RT @BryanDChoi: Today, @NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEA…
0
190
0
RT @DKFZ: Forschende des @uniklinik_hd und DKFZ identifizieren genetische Signatur, die für Tumorzellen von #Glioblastom|en typisch ist. Du…
0
1
0
RT @NatureComms: .@DirkCHoffmann @wick_wolfgang et al. at @DKFZ @HdNeurooncology combine a dye uptake method and #scRNAseq to infer a tumor…
0
5
0
RT @DirkCHoffmann: As part of my PhD thesis @wick_wolfgang lab @DKFZ, @uniklinik_hd, @UniHeidelberg, @HdNeurooncology we investigated the c…
0
28
0
Important study and a promising novel therapeutic avenue for EBV associated DLBCL. ORR was 51% in a pretreated PTLD population. Combination with targeted therapy may be key given CR rate of 28%? No firm conclusions about CNS disease yet. @HdNeurooncology
NOW OF The ALLELE open-label phase 3 trial of tabelecleucel for allogeneic HSCT or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy.
0
0
4
RT @NatureMedicine: Profiling a case of secondary T cell lymphoma following anti-CD19 #CARTcells suggests this was not caused by CAR insert…
0
34
0
RT @DrChrisPFox: A great team effort: LBCL is getting complicated! R/R guideline to follow.... @AndyD1036 @Sridha…
0
22
0
RT @BWHNeurology: The International Primary CNS Lymphoma Collaborative Group (IPCG), co-founded by @tracytbatchelor, Franco Cavalli, and Ja…
0
2
0
RT @wick_wolfgang: We are extremely grateful to the foundation, all great clinicians and scientists as well as patients supporting science.…
0
6
0
0
0
0
Really grateful for this fantastic collaborative effort @wick_wolfgang @HdNeurooncology @DKFZ @sahm_lab @uniklinik_hd @ResearchLifesci and many more + financial support from the @DKFZ clinician scientist program supported by the Dieter Morszeck foundation. Stay tuned for more…
0
1
3